Cracking the complex tumor microenvironment

BeyondSpring Pharmaceuticals’ plinabulin demonstrates a multifaceted approach that targets immune and vascular aspects of tumor growth, resulting in immune-enhancing effects.

Like Comment
Page of
Go to the profile of BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. We are advancing our lead asset, an immuno-oncology agent Plinabulin, in a global Phase 3 clinical trial for the reduction of Docetaxel-induced Neutropenia and another Phase 3 clinical trial as an anticancer agent in combination with Docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin is also entering Phase 1/2 clinical trials to investigate its therapeutic potential in immuno-oncology. Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, we are well-positioned for expeditious progress to NDA and commercialization.

No comments yet.